



I INTERNATIONAL LUNG CANCER DEBATES 2023

**3 and 4 february 2023, Las Palmas de Gran Canaria.
Canary Islands**

VENUE:

Gabinete Literario

Plaza de Cairasco, 1. Las Palmas de Gran Canaria.



**PARA MÁS INFORMACIÓN ACCEDA
A LA WEB DEL CONGRESO AQUÍ**

SCIENTIFIC COORDINATORS

Dr. Delvys Rodríguez Abreu

Hospital Universitario Insular de Gran Canaria, Spain

Dr. Rosario García Campelo

Complejo Hospitalario Universitario de A Coruña, Spain

ORGANIZED BY





I INTERNATIONAL LUNG CANCER DEBATES 2023

03
FRIDAY

10:30 – 11:00 **Registration**

11:00 – 11:15 **Institutional opening and introduction**

Dr. Delvys Rodríguez Abreu

Hospital Universitario Insular de Gran Canaria, Spain

Dr. Rosario García Campelo

Complejo Hospitalario Universitario de A Coruña, Spain

11:15 – 12:45 **SESSION I – TARGET THERAPIES**

Chairs:

Dr. Javier de Castro

Hospital Universitario La Paz, Madrid, Spain

Dr. Sergio Vázquez

Hospital Universitario Lucus Augusti de Lugo, Spain

11:15 – 11:30 **How biomarkers are changing the lung cancer landscape?**

Dr. Fernando López-Ríos

Hospital Universitario 12 de Octubre, Madrid, Spain

11:30– 11:45 **EGFRm NSCLC. Many different diseases**

Dr. Alfredo Addeo

Hopitaux Universitaires de Genève, Switzerland

11:45 – 12:00 **ALK NSCLC and ROS1. Too many options in 1L. Which one is better?**

Dr. Lorenza Landi

National Cancer Institute Regina Elena, Rome, Italy

12:00 – 12:15 **RET, MET and NTKR in NSCLC. Small groups but big patients' opportunities**

Dr. Jordi Remon

Institut Gustave Roussy, Paris, France

12:15 – 12:30 **KRAS and HER2 NSCLC. Finally in clinic**

Dr. Anna Estival

Hospital Universitario Insular de Gran Canaria, Spain

12:30 – 12:45 **Discussion and Q&A**

12:45 – 13:40

SESSION II – EARLY AND LOCALLY ADVANCED NSCLC

Chairs:

Dr. Antonio Araújo

Centro Hospitalar Universitário do Porto, Portugal

Dr. Reyes Bernabé

Hospital Universitario Virgen del Rocío, Sevilla, Spain

12:45 – 13:00

Are we ready to start with IO in adjuvant?

Dr. Federico Cappuzzo

National Cancer Institute Regina Elena, Rome, Italy

13:00 – 13:15

Neoadjuvant Immuno better than adjuvant?

Dr. Benjamin Levy

Johns Hopkins Kimmel Cancer Center, Washington, USA

13:15 – 13:30

Secuencial or Concurrent Immuno/Radio. Which one is better?

Dr. Raffaele Califano

The Christie NHS Foundation Trust, Manchester, UK

13:30 – 13:40

Discussion and Q&A

13:40 – 15:00

LUNCH



15:00 – 16:45

SESSION III – IMMUNOTHERAPY IN ADVANCED NSCLC

Chairs:

Dr. Delvys Rodríguez Abreu

Hospital Universitario Insular de Gran Canaria, Spain

Dr. Martín Lázaro

Complejo Hospitalario Universitario de Vigo

15:00 – 15:30

In PD-L1>50%. The same question: mono vs combo

Dr. Ignacio Gil-Bazo

Fundación Instituto Valenciano de Oncología (IVO), Spain
vs

Dr. Hossein Borghaei

Fox Chase Cancer Center, Philadelphia, USA



15:30 – 16:00 In Nsq CT/IO vs IO/IO

Dr. Francesco Passiglia

Università degli Studi di Torino, Italy

vs

Dr. Manuel Cobo

Hospital Regional Universitario y Virgen de la Victoria,
Málaga, Spain

16:00 – 16:30 In Sq CT/IO vs IO/IO

Dr. Xabier Mielgo

Hospital Universitario Fundación Alcorcón, Madrid, Spain

vs

Dr. Enric Carcereny

Hospital Universitario Germans Trias i Pujol, Badalona, Spain

16:30 – 16:45 Discussion and Q&A

16:45 – 17:15 COFFEE BREAK



17:15 – 18:25

SESSION IV – OTHER THORACIC TUMORS

Chairs:

Dr. José Luis González Larriba

Hospital Clínico Universitario San Carlos, Madrid, Spain

Dr. Dolores Isla

Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain

17:15 – 17:30

How to improve 1L treatment in mSCLC?

Dr. Stephen Liu

Georgetown Lombardi Comprehensive Cancer Center,
Washington, USA

17:30 – 17:45

Second-line treatment in SCLC?

Dr. José Manuel Trigo

HC Marbella International Hospital, Málaga, Spain

17:45 - 18:00 **Mesothelioma: is immunotherapy changing the paradigm?**

Dr. Noemí Reguart

Hospital Clínic Barcelona, Spain

18:00 - 18:15 **Brain metastasis: is immunotherapy changing the paradigm?**

Dr. Ernest Nadal

(ICO) Hosp. Duran i Reynald, Hospitalet de Llobregat,
Barcelona, Spain

18:15 - 18:25 **Discussion and Q&A**

18:25 - 18:30 **DAY CLOSING**



10:00 - 11:25

SESSION V – MISCELLANEOUS

Chairs:

Dr. Bartomeu Massuti

Hospital Universitario Dr. Balmis, Alicante, Spain

TBD

10:00 - 10:15

Primary and acquired resistance to immunotherapies

Dr. Jarushka Naidoo

Beaumont RCSI Cancer Centre, Dublin, Ireland

10:15 - 10:30

Too many biomarkers in IO but how many do we really use?

Dr. Miguel Fernández de Sanmamed

Cima Universidad de Navarra, Spain

10:30 - 10:45

New options after IO failure

Dr. Rosario García Campelo

Complejo Hospitalario Universitario de A Coruña, Spain

10:45 - 11:00

Antibody drug conjugates and Bispecific antibodies in lung cancer

Dr. Antonio Calles

Hospital General Universitario Gregorio Marañón, Madrid, Spain

11:00 - 11:15

Do we need better endpoint in clinical trial with Immunotherapy?

Dr. Ana Arance

Hospital Clinic Barcelona, Spain

11:15 - 11:25

Discussion and Q&A

11:25 - 11:40

CLOSING REMARKS

Dr. Delvys Rodríguez Abreu

Hospital Universitario Insular de Gran Canaria, Spain

Dr. Rosario García Campelo

Complejo Hospitalario Universitario de A Coruña, Spain

CON EL AVAL CIENTÍFICO DE



SEOM
Sociedad Española
de Oncología Médica



Comisión Canaria de
Formación Continua
de las Profesiones Sanitarias

Solicitada la Acreditación de la Formación Continuada de las Profesiones Sanitarias de la Comunidad Autónoma de Canarias. La asistencia presencial durante todo el evento es obligatoria para obtener la acreditación. No recibirán los créditos del sistema acreditador ni estudiantes, ni médicos internos residentes, ya que están excluidos del mismo.

Secretaría Técnica

Silk.

Plaza de la Feria, 40, 5º Dcha.
Las Palmas de GG, 35003, España
Tel: 828 90 40 61 /+ 34 682 42 73 40
Mail: gccpsectec@silkmarketing.es
www.silkmarketing.es

Agencia Colaboradora

